Equities research analysts expect K2M Group Holdings, Inc. (NASDAQ:KTWO) to announce earnings per share (EPS) of ($0.22) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for K2M Group Holdings’ earnings. The lowest EPS estimate is ($0.23) and the highest is ($0.20). K2M Group Holdings reported earnings of ($0.27) per share during the same quarter last year, which indicates a positive year over year growth rate of 18.5%. The business is scheduled to issue its next earnings report after the market closes on Tuesday, August 1st.

According to Zacks, analysts expect that K2M Group Holdings will report full-year earnings of ($0.80) per share for the current fiscal year, with EPS estimates ranging from ($0.86) to ($0.75). For the next year, analysts expect that the company will post earnings of ($0.37) per share, with EPS estimates ranging from ($0.53) to ($0.25). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for K2M Group Holdings.

K2M Group Holdings (NASDAQ:KTWO) last posted its earnings results on Tuesday, May 2nd. The medical device company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.02. The business had revenue of $61.89 million for the quarter, compared to analysts’ expectations of $60.10 million. K2M Group Holdings had a negative return on equity of 16.02% and a negative net margin of 17.48%.

KTWO has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded K2M Group Holdings from a “sell” rating to a “hold” rating in a research note on Thursday, March 23rd. Cowen and Company restated an “outperform” rating and set a $26.00 price objective (up previously from $21.00) on shares of K2M Group Holdings in a research note on Sunday, April 9th. JMP Securities reiterated an “outperform” rating and issued a $27.00 target price on shares of K2M Group Holdings in a research report on Wednesday, April 12th. Barclays PLC lifted their target price on K2M Group Holdings from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, April 24th. Finally, Royal Bank Of Canada reiterated a “buy” rating on shares of K2M Group Holdings in a research report on Wednesday, May 3rd. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. K2M Group Holdings presently has a consensus rating of “Buy” and a consensus price target of $25.88.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect K2M Group Holdings, Inc. (NASDAQ:KTWO) to Announce -$0.22 EPS” was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/07/20/zacks-analysts-expect-k2m-group-holdings-inc-nasdaqktwo-to-announce-0-22-eps.html.

K2M Group Holdings (NASDAQ KTWO) traded up 0.97% during midday trading on Thursday, reaching $25.00. The company had a trading volume of 302,250 shares. The firm’s 50-day moving average price is $23.64 and its 200 day moving average price is $21.65. K2M Group Holdings has a 12 month low of $15.45 and a 12 month high of $25.18. The firm’s market capitalization is $1.06 billion.

In related news, insider John Philip Md Kostuik sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $22.70, for a total value of $1,135,000.00. Following the sale, the insider now owns 199,107 shares of the company’s stock, valued at approximately $4,519,728.90. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Gregory S. Cole sold 42,947 shares of the firm’s stock in a transaction that occurred on Friday, June 16th. The stock was sold at an average price of $22.80, for a total value of $979,191.60. Following the completion of the sale, the chief financial officer now directly owns 87,425 shares in the company, valued at approximately $1,993,290. The disclosure for this sale can be found here. In the last quarter, insiders sold 95,805 shares of company stock valued at $2,178,713. Insiders own 5.80% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. TimesSquare Capital Management LLC increased its stake in shares of K2M Group Holdings by 44.0% in the first quarter. TimesSquare Capital Management LLC now owns 2,197,020 shares of the medical device company’s stock valued at $45,061,000 after buying an additional 671,120 shares during the period. Citadel Advisors LLC increased its stake in shares of K2M Group Holdings by 3,357.5% in the first quarter. Citadel Advisors LLC now owns 628,808 shares of the medical device company’s stock valued at $12,897,000 after buying an additional 610,621 shares during the period. JPMorgan Chase & Co. increased its stake in shares of K2M Group Holdings by 54.3% in the first quarter. JPMorgan Chase & Co. now owns 1,409,360 shares of the medical device company’s stock valued at $28,906,000 after buying an additional 495,749 shares during the period. Next Century Growth Investors LLC increased its stake in shares of K2M Group Holdings by 134.8% in the first quarter. Next Century Growth Investors LLC now owns 553,654 shares of the medical device company’s stock valued at $11,355,000 after buying an additional 317,878 shares during the period. Finally, Point72 Asset Management L.P. increased its stake in shares of K2M Group Holdings by 114.0% in the first quarter. Point72 Asset Management L.P. now owns 555,500 shares of the medical device company’s stock valued at $11,393,000 after buying an additional 295,900 shares during the period. 98.75% of the stock is currently owned by institutional investors and hedge funds.

About K2M Group Holdings

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Get a free copy of the Zacks research report on K2M Group Holdings (KTWO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.